Show simple item record

dc.contributor.authorRenehan, Andrew G
dc.contributor.authorMuirhead, R
dc.contributor.authorBerkman, L
dc.contributor.authorMcParland, L
dc.contributor.authorSebag-Montefiore, D
dc.date.accessioned2019-03-04T12:32:42Z
dc.date.available2019-03-04T12:32:42Z
dc.date.issued2019en
dc.identifier.citationRenehan AG, Muirhead R, Berkman L, McParland L, Sebag-Montefiore D, PLATO trial management group. Early stage anal margin cancer: towards evidence-based management. Colorectal Dis. 2019 Jan 27.en
dc.identifier.pmid30687991en
dc.identifier.doi10.1111/codi.14571en
dc.identifier.urihttp://hdl.handle.net/10541/621561
dc.description.abstractAnal squamous cell carcinoma is an uncommon Human Papilloma Virus (HPV)-related malignancy, the incidence of which has increased two- to four-fold over the past three decades. Results from the first three phase III trials, performed in the 1990s (the largest being the ACT I trial in the UK), established concurrent mitomycin C (MMC), 5-fluorouracil chemotherapy and radiotherapy (CRT) as the main primary treatment. Three subsequent trials (including ACT II in the UK, performed between 1998 and 2008, demonstrated evidence of no benefit from the use of additional chemotherapy before or after CRT, or concurrent cisplatin. This article is protected by copyright. All rights reserved.en
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.1111/codi.14571en
dc.titleEarly stage anal margin cancer: towards evidence-based management.en
dc.typeArticleen
dc.contributor.departmentDivision of Cancer Sciences, School of Medical Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, United Kingdomen
dc.identifier.journalColorectal Diseaseen
dc.description.noteen]


This item appears in the following Collection(s)

Show simple item record